Drug Pipeline

Alisertib Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
1
Recruiting
3
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-06 NCT06095505
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer		 Enrollment increased: 80 -> 120 participants
2026-06-06 NCT06095505
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer		 date change Primary completion pushed: 2027-04-30 -> 2027-10-30
2026-06-06 NCT06095505
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer		 date change Completion pushed: 2027-10-31 -> 2028-04-30
Active Studies by Phase
Phase 2
3
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06095505 A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer Small Cell Lung Cancer Recruiting
NCT07465757 A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) Small Cell Lung Cancer ( SCLC ) Not Yet Recruiting
NCT02114229 Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors Malignant Rhabdoid Tumor Active, Not Recruiting
Phase 1
NCT01695941 Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory… Recurrent B-Cell Non-Hodgkin Lymphoma Active, Not Recruiting
Sponsors Running Alisertib Trials
Puma Biotechnology, Inc. (2) National Cancer Institute (NCI) (1) St. Jude Children's Research Hospital (1)
Disease Areas
Small Cell Lung Cancer (2) Lung Cancer (2) Non-Hodgkin Lymphoma (1) Mantle Cell Lymphoma (1)
Get alerts when Alisertib trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free